Archive for 'Press Releases'
LAVIV™ (azficel-T) Demonstrates Improvement in Acne Scarring
New Data Show Personalized Cell Therapy Offers Potential New Treatment Approach EXTON, Pa., November 03, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, today announced the first scientific presentation of data demonstrating the efficacy of LAVIV™ (azficel-T) in treatingRead more
Fibrocell Science, Inc. Announces Launch of LAVIV™ (azficel-T)
Consumer Website, mylaviv.com, Now Live Conference call to discuss LAVIV business strategy to be held October 4, 2011 at 5:00 PM EXTON, Pa., October 03, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), a cell therapy company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that it hasRead more
Fibrocell Science, Inc.’s LAVIV™ (azficel-T) Wins a 2011 Allure Best of Beauty Award
LAVIV™ Named as One of 14 Big Breakthroughs in 2011 EXTON, Pa., September 28, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), a cell therapy company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that LAVIV™ (azficel-T) has been named a 2011 Allure Breakthrough Award winner. LAVIV™ isRead more
Fibrocell Science, Inc. Announces New Presentation Time at the UBS Global Life Sciences Conference
EXTON, Pa.- Fibrocell Science, Inc. (OTCBB:FCSC.OB) a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that its presentation at the UBS Global Life Sciences Conference to be held on September 19-21, 2011 at the Grand Hyatt Hotel in New York has been rescheduled toRead more
Fibrocell Science, Inc. to Present at the UBS Global Life Sciences Conference
EXTON, Pa.- Fibrocell Science, Inc. (OTCBB:FCSC.OB) a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the UBS Global Life Sciences Conference to be held on September 19-21, 2011 at the Grand HyattRead more
Fibrocell Science, Inc. Announces New Presentation Time at the Kaufman Bros. 14th Annual Investor Conference
EXTON, Pa.- Fibrocell Science, Inc. (OTCBB:FCSC.OB) a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that its presentation at the Kaufman Bros. 14th Annual Investor Conference to be held on September 7-8, 2011 at the W Hotel New York has been rescheduled to aRead more
Fibrocell Science, Inc. to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
EXTON, Pa.- Fibrocell Science, Inc. (OTCBB:FCSC.OB) a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Rodman & Renshaw 13th Annual Healthcare Conference to be held on September 11-13, 2011 at TheRead more
Fibrocell Science, Inc. to Present at the Kaufman Bros. 14th Annual Investor Conference
EXTON, Pa.- Fibrocell Science, Inc. (OTCBB:FCSC.OB) a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Kaufman Bros. 14th Annual Investor Conference to be held on September 7-8, 2011 at the WRead more
Fibrocell Science, Inc. to Host Investor Conference Call to Discuss Business Update
EXTON, Pa.- Fibrocell Science, Inc. (OTCBB:FCSC.OB) a cell therapy company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will host an investor conference call to discuss Fibrocell’s business update and growth strategy on Wednesday, August 24, 2011 atRead more
Fibrocell Science, Inc. to Raise $22.7 Million in Private Placement
EXTON, Pa.- Fibrocell Science, Inc. (OTCBB:FCSC.OB) announced today that the Company has entered into a definitive Securities Purchase Agreement with certain accredited investors, pursuant to which the Company agreed to sell to the purchasers an aggregate of 41,245,822 shares of Company common stock at a purchase price of $0.55 per share in a private placement.Read more